Oligoclonal Band Status and Features of Radiological and Clinical Findings in Patients with Multiple Sclerosis in Lithuania
暂无分享,去创建一个
[1] L. Ramió-Torrentá,et al. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis. , 2022, Multiple sclerosis and related disorders.
[2] Ovidijus Laucius,et al. Factors Related to the Progression of Clinically Isolated Syndrome to Multiple Sclerosis: A Retrospective Study in Lithuania , 2022, Medicina.
[3] Elif Söylemez,et al. The Effect of Oligoclonal Bands in Patients with Multiple Sclerosis , 2022, Türk Nöroloji Dergisi.
[4] E. Thouvenot,et al. Biological Markers in Early Multiple Sclerosis: the Paved Way for Radiologically Isolated Syndrome , 2022, Frontiers in Immunology.
[5] M. Magyari,et al. Aging With Multiple Sclerosis: Age-Related Factors and Socioeconomic Risks , 2022, Frontiers in Neurology.
[6] T. Shiner,et al. Reinforcing the evidence of oligoclonal bands as a prognostic factor in patients with Multiple sclerosis. , 2021, Multiple sclerosis and related disorders.
[7] B. Uitdehaag,et al. MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis , 2021, Multiple sclerosis.
[8] J. Newton,et al. Cardiac Autonomic Dysfunction in Myasthenia Gravis and Relapsing-Remitting Multiple Sclerosis—A Pilot Study , 2021, Journal of clinical medicine.
[9] J. Hillert,et al. Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study , 2021, Scientific Reports.
[10] C. Falup-Pecurariu,et al. Autonomic dysfunctions in multiple sclerosis: Challenges of clinical practice (Review). , 2020, Experimental and Therapeutic Medicine.
[11] M. Sormani,et al. Predicting disability progression in multiple sclerosis: Insights from advanced statistical modeling , 2020, Multiple sclerosis.
[12] E. Leray,et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.
[13] B. Combès,et al. Prognostic value of spinal cord MRI in multiple sclerosis patients. , 2020, Revue neurologique.
[14] A. Kermode,et al. Advanced MRI features in relapsing multiple sclerosis patients with and without CSF oligoclonal IgG bands , 2020, Scientific Reports.
[15] T. Vollmer,et al. Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides , 2020, PloS one.
[16] E. Celius,et al. The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis , 2020, Multiple sclerosis journal - experimental, translational and clinical.
[17] D. Arnold,et al. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis , 2019, Brain : a journal of neurology.
[18] F. Barkhof,et al. Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability? , 2019, Multiple sclerosis.
[19] A. Kermode,et al. Comparison of multiple sclerosis patients with and without oligoclonal IgG bands in South China , 2019, Journal of Clinical Neuroscience.
[20] O. Ciccarelli,et al. Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines , 2019, Brain : a journal of neurology.
[21] R. Bakshi,et al. Magnetic Resonance Imaging in Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.
[22] T. Akaishi,et al. Oligoclonal bands and periventricular lesions in multiple sclerosis will not increase blood-brain barrier permeability , 2018, Journal of the Neurological Sciences.
[23] H. Siebner,et al. Disability in progressive MS is associated with T2 lesion changes. , 2018, Multiple sclerosis and related disorders.
[24] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[25] À. Rovira,et al. Juxtacortical Lesions and Cortical Thinning in Multiple Sclerosis , 2015, American Journal of Neuroradiology.
[26] Neeta Garg,et al. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis , 2015, Brain and behavior.
[27] David H. Miller,et al. Spinal cord MRI in multiple sclerosis—diagnostic, prognostic and clinical value , 2015, Nature Reviews Neurology.
[28] Ludwig Kappos,et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis , 2015, Neurology.
[29] E. Eren,et al. Comparison of neurophysiological and MRI findings of patients with multiple sclerosis using oligoclonal band technique , 2013, Annals of neurosciences.
[30] M. Sormani,et al. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.
[31] H. Tremlett,et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression , 2013, Multiple sclerosis.
[32] G. Giovannoni,et al. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[33] J. Hillert,et al. Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients , 2013, Journal of Neuroimmunology.
[34] A. Damasceno,et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients , 2012, Multiple sclerosis.
[35] N. Kale,et al. Electrophysiological and clinical correlates of corpus callosum atrophy in patients with multiple sclerosis , 2010, Neurological research.
[36] P. Sørensen,et al. The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.
[37] L. Roccatagliata,et al. MR peri‐CSF lesions and CSF oligoclonal bands in Italian multiple sclerosis patients , 2009, Acta neurologica Scandinavica.
[38] W. Valdar,et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study , 2006, The Lancet Neurology.
[39] Rohit Bakshi,et al. The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.
[40] Jonathan Taylor,et al. Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis: application to 452 patient data sets , 2003, NeuroImage.
[41] E. Leray,et al. Epidemiology of multiple sclerosis. , 2016, Revue neurologique.